- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
10/5/07 11:06 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Thursday, October 18. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2007 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visitmore...
10/4/07 9:00 am EDT
Pfizer Launches Independent Biotherapeutics and Bioinnovation Center, Headed by Dr. Corey Goodman
Dr. Briggs Morrison Named Head of Clinical DevelopmentNEW YORK--(BUSINESS WIRE)--Pfizer today named Dr. Martin Mackay as President of Pfizer Global Research and Development (PGRD); launched an independent, stand-alone biotherapeutics and bioinnovation center under the direction of scientist and entrepreneur Dr. Corey Goodman; and named Dr. Briggs Morrison, who held senior research and development positions at Merck, as its new Head of Clinical Development for the PGRD pipeline. “As themore...
10/3/07 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer announced today that Dr. Tanya Clemons, a senior executive with extensive experience in leadership and organization change at Microsoft and IBM, will join Pfizer as vice president and Chief Talent Officer in November. Dr. Clemons will report to Mary McLeod, the senior vice president for Worldwide Talent Development and Human Resources. She will be a member of the Human Resources Leadership Team and Pfizermore...
9/28/07 12:32 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s second medical use patent covering Viagra would be infringed by Apotex’ proposed generic product. The court granted the company’s application for an order preventing Apotex from launching a generic version of Viagra until expiration of Canadian Patent No. 2,163,446 in 2014. The decision is subject tomore...
9/28/07 11:59 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that in recognition for its approach to improving the environment, the company was named to the Climate Disclosure Leadership Index (CDLI) by the Carbon Disclosure Project (CDP), a not-for-profit coalition of more than 315 global investors. Pfizer was one of 68 Fortune 500 companies -- and the only pharmaceutical company -- named in the CDLI, a prestigious honor roll for global corporationsmore...
9/27/07 12:01 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the election of Suzanne Nora Johnson and James M. Kilts to the Pfizer Board of Directors effective September 27, 2007. Ms. Johnson, 50, retired as Vice Chairman of The Goldman Sachs Group Inc. in January 2007. She had been with the firm for 21 years in roles ranging from the head of health care investment banking to the head of global research and the Chairman of the Global Marketsmore...
New Preliminary Phase II Data Show Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer9/26/07 8:00 am EDT
Additional Early Data Show the Tolerability of Sunitinib in Combination with Standard of Care Chemotherapies in the Treatment of Advanced Prostate and Breast CancersNEW YORK--(BUSINESS WIRE)--Preliminary results from a new Phase II study provide data on the anti-tumor activity and tolerability of sunitinib malate in patients with advanced gastric cancer. Additionally, data from phase I studies provide information on the tolerability and safety of sunitinib malate in combination with current standard of care chemotherapies in the treatment of hormone-refractory prostate cancer (HRPC) and advancedmore...
Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients9/24/07 3:00 am EDT
First in a New Oral Class of HIV Medicines in 10 YearsNEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the European Commission (EC) has approved Celsentri® (maraviroc). Treatment-experienced HIV patients in the EU can soon benefit from the first CCR5 antagonist and only oral entry inhibitor. Maraviroc, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 virus detectable.more...
9/21/07 2:08 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that an appeals court has overturned a lower court ruling that several generic manufacturers did not infringe the company’s patent for stabilized formulations of gabapentin, the active ingredient in Neurontin. The Court of Appeals for the Federal Circuit ruled that the New Jersey federal district court should not have granted summary judgment to the generic manufacturers, and that a fullmore...
Pfizer and the European Foundation for the Study of Diabetes Announce a New Research Program Focused on Cardiovascular Risk in Patients with Diabetes9/21/07 3:00 am EDTAMSTERDAM, Netherlands--(BUSINESS WIRE)--Pfizer and the European Foundation for the Study of Diabetes (EFSD) announced today, at the European Association for the Study of Diabetes (EASD) Annual Meeting, the development of a new awards program which will provide research grants to support European research around understanding and reducing cardiovascular risk in patients with diabetes. Grants will be awarded for, but not limited to, research focusingmore...